The stock's fall snapped a three-day winning streak.

A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in ...

Arish Global Services, the all-in-one solution for web lead generation based in the UK, announced today its partnership with ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...

Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

This was the stock's third consecutive day of gains.

Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Vertex (VERX – Research Report) received a Hold rating and price target from Raymond James analyst Alexander Sklar today. The company’s ...